shares of lexicon pharmaceuticals inc gained in thursdays afterhours market following news the company submitted a new drug application for sotagliflozin to the us food and drug administration at 415 pm et the companys shares were trading 7 higher at 446 the stock finished the days regulartrading session with a 17 gain closing at 417 a share the company said the nda was seeking approval to market and sell sotagliflozin to reduce the risk of cardiovascular death and of hospitalization or urgent visits for heart failure in certain adult patients with type 2 diabetes sotagliflozin is approved in the european union for use as an adjunct to insulin therapy to improve blood sugar control in certain adults with type 1 diabetes but hasnt been commercially launched the biopharmaceutical company said